Merck
CN

Development of the loratadine gel for enhanced transdermal delivery.

Drug development and industrial pharmacy (2009-02-26)
Jae-Haeng Song, Sang-Chul Shin
摘要

The oral administration of loratadine, an antihistamine, can have a variety of adverse side effects, such as headache, fatigue, and nausea, because of the transient high blood concentration. To avoid these effects, loratadine can be administered using a transdermal drug delivery system. This study examined the effects of the drug concentration on drug release from prepared hydroxypropyl methylcellulose gels using a synthetic cellulose membrane at 37 degrees C. The drug concentrations tested were 0.1%, 0.2%, 0.3%, 0.4%, and 0.5% (w/w). The effect of temperature on drug release from the 0.3% loratadine gels was evaluated at 27 degrees C, 32 degrees C, 37 degrees C, and 42 degrees C. Various types of penetration enhancers, such as glycols, glycerides, propylene glycol derivatives, nonionic surfactants, and fatty acids, were incorporated in the gel formulation to increase the level of drug permeation. The rate of drug release increased with increasing drug concentration or temperature. The activation energy for the release of the drug was 5.714 kcal/mol for 0.3% loratadine gel. Among all the enhancers used in this study, polyoxyethylene 2-stearyl ether showed the best enhancing effect. The enhancement factor of the loratadine gel containing the polyoxyethylene 2-stearyl ether was 2.03 compared with that of the loratadine system containing no enhancer. These results suggest that the topical gel formulation of loratadine containing a penetration enhancer could be developed to enhance the penetration of loratadine.

材料
货号
品牌
产品描述

Sigma-Aldrich
Brij® S20
Sigma-Aldrich
Brij® S 100, average Mn ~4,670
Sigma-Aldrich
SP Brij® S2 MBAL, main component: diethylene glycol octadecyl ether
Sigma-Aldrich
Brij ® S10, average Mn ~711
Sigma-Aldrich
Brij® S 100, average Mn ~4,670
Sigma-Aldrich
Brij® S20
Sigma-Aldrich
Brij ® S10, average Mn ~711